The United States healthcare system has experienced an expansion of private equity ownership. In new research, Theodosia Stavroulaki argues that private equity acquisitions risk harming healthcare by increasing prices, reducing quality of care, limiting access to care, and hurting the labor force.

Public investors poured funds into buying SpaceX shares upon its mid-June IPO, and they can be expected to continue to do so heavily over...

The draft EU Merger Guidelines open merger analysis to non-economic considerations, including choice, supply chain resilience, and sustainability. However, they do not yet explain how these considerations will be paired with a traditional consumer welfare analysis of price and quantity. Maciej Bernatt and Simbarashe Tavuyanago look to South Africa to devise a “vulnerable consumer test” that can help bridge these economic and non-economic goals.

Investors have poured billions into using artificial intelligence to discover new drugs, and 2026 is the first real test of whether AI-designed medicines actually helps patients. The boom has genuinely transformed the search for molecules — but that was never the costly, failure-prone part of making a medicine, and there AI has so far had little to add. Capital, and the public subsidies have not yet priced the difference, writes Michael A. Santoro.

Microsoft CEO Satya Nadella’s argument that businesses need to be able to easily switch between artificial intelligence models is correct but elides the fact,...

In new research, Vishavdeep Sharma and Krishnendu Ghosh Dastidar analyze corporate corruption through the lens of market competition. Firms often bribe officials to block rivals from entering their markets, and their incentive to do so depends less on how competitive a market is than on what kind of competition it has.